High-flow Nasal Cannula as an Alternative Intervention for Children and Adolescents With Obstructive Sleep Apnoea
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- Efficacy of the high flow nasal cannula (HFNC) therapy: the absolute change in obstructive apnea hypopnea index (OAHI) from baseline with the use of HFNC therapy
研究概览
简要总结
The main objective of this study is to evaluate the efficacy of high-flow nasal cannula (HFNC) therapy in children with OSA.
Children and adolescents aged 6 to 18 years old with a diagnosis of moderate-to-severe OSA requiring CPAP therapy will be recruited.
In phase 1 study, eligible subject will be recruited for HFNC therapy titration with PSG to assess treatment efficacy. After titration, if HFNC therapy is shown to be effective, the participants will be recruited into the phase 2 intervention period to evaluate the compliance and quality of life with HFNC therapy. At baseline and follow-up visits, neurobehavioural and quality of life surveys will be completed, compliance data will be obtained.
详细描述
Background: Obstructive sleep apnoea (OSA) is prevalent in school-aged children and is associated with significant morbidities. Poor compliance with positive airway pressure therapy remains an issue and leads to suboptimal treatment in children with OSA. Alternative therapeutic strategy is needed to manage this group of patients more effectively.
Objective: To evaluate the efficacy of high-flow nasal cannula (HFNC) therapy in children with OSA.
Hypothesis: The investigators hypothesize that HFNC therapy is effective in reducing the severity of OSA in children.
Design: A 2-phase study - phase 1 is a single arm study to evaluate the efficacy of HFNC therapy in children with OSA, phase 2 is an intervention period to evaluate the compliance and quality of life with HFNC therapy.
Subjects: 46 children and adolescents aged 6 to 18 years old with a diagnosis of moderate-to-severe OSA requiring CPAP therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 6 Years 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of moderate-to-severe OSA requiring CPAP therapy (Moderate-to-severe OSA is defined as an OAHI ≥ 5 events per hour and reported history of habitual snoring of 3 nights or more per week)
排除标准
- •Syndromal diseases;
- •Cranio-facial anomalies;
- •Pathological central apnoea, chronic respiratory failure or neuromuscular disease as they would require bilevel PAP;
- •Secondary obesity e.g. Prader-Willi syndrome, Cushing's syndrome;
- •History of pneumothorax or pneumomediastinum;
- •Prior use of PAP or HFNC therapy;
- •Refusal to use non-invasive ventilation.
结局指标
主要结局
Efficacy of the high flow nasal cannula (HFNC) therapy: the absolute change in obstructive apnea hypopnea index (OAHI) from baseline with the use of HFNC therapy
时间窗: One night - titration study will be done overnight for one night to look at the improvement of OAHI from baseline to that with HFNC therapy
The change in obstructive apnea hypopnea index (OAHI) from baseline to that on HFNC therapy: obstructive apnoea hypopnoea index is the number of obstructive apnoea or hypopnoea events per hour of total sleep time (It is not a scale, minimum is 0 events/hour, there is no maximum score)
次要结局
- Compliance to the therapy: percentage of subjects who are adherent to the therapy(3 months)
- Neurobehavioural surveys - Child Behaviour Checklist(3 months)
- Quality of life measures - Modified Epworth Sleepiness Scale(3 months)
- Quality of life measures - Pediatric Quality of Life Inventory(3 months)
- Quality of life measures - OSAS-18(3 months)
研究者
Kate Ching Ching Chan
Associate Professor
Chinese University of Hong Kong